0.00Open0.00Pre Close0 Volume0 Open Interest17.50Strike Price0.00Turnover288.72%IV-70.57%PremiumDec 20, 2024Expiry Date7.24Intrinsic Value100Multiplier11DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7936Delta0.0560Gamma1.33Leverage Ratio-0.0651Theta-0.0039Rho-1.06Eff Leverage0.0051Vega
Y-mAbs Therapeutics Stock Discussion
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
Y-mAbs Therapeutics (NASDAQ: YMAB)presented preclinical data and trial progress for its CD38-SADA platform at the 2024 ASH Annual Meeting. The preclinical data demonstrated selective binding and anti-tumor efficacy of CD38-SADA when used with Lutetium 177-DOTA in treating Non-Hodgkin Lymphoma (NHL).
The company also...
No comment yet